Summary of Issues
Considering both the 4 mg and 8/4 mg arms, how convincing is Study 039?
This is a first indication of a bisphosphonate for a predominantly osteoblastic disease. Can support be drawn from other trials?
Is there substantial evidence to support efficacy of the 4 mg arm?